Jie Jiang

Title: Jie Jiang - Innovator in Kinase Inhibition

Introduction

Jie Jiang is a prominent inventor based in Brookline, MA, known for his significant contributions to the field of kinase inhibition. His work focuses on developing compounds that can selectively inhibit cyclin-dependent kinase 7 (CDK7), which has implications for treating various diseases.

Latest Patents

Jie Jiang holds a patent titled "Inhibitors of cyclin-dependent kinase 7 and uses thereof." This patent discloses compounds of Formula (I), along with their pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs. The compounds are designed to selectively inhibit the activity of CDK7 over other kinases such as CDK2, CDK9, and CDK12. The patent also outlines pharmaceutical compositions, kits, and methods of use that involve these compounds, which may be useful in inhibiting kinase activity, down-regulating transcription of MYC or MCL-1, inhibiting cell growth, inducing apoptosis, and treating or preventing diseases like proliferative diseases and cystic fibrosis.

Career Highlights

Jie Jiang is affiliated with the Dana-Farber Cancer Institute Inc., where he continues to advance his research in kinase inhibitors. His innovative work has positioned him as a key figure in the development of therapeutic strategies targeting CDK7.

Collaborations

Jie Jiang collaborates with notable colleagues such as Nathanael Schiander Gray and Tinghu Zhang, contributing to a dynamic research environment focused on cancer treatment and drug development.

Conclusion

Jie Jiang's contributions to the field of kinase inhibition through his patent and research at the Dana-Farber Cancer Institute highlight his role as an influential inventor. His work has the potential to impact the treatment of various diseases significantly.